ILLUMINA, INC. (ILMN): M&A transaction — Illumina completes $350M acquisition of SomaLogic from Standard BioTools

ILLUMINA, INC.

Purchase price $350M in cash plus up to $75M in performance milestones and royalties.
SomaLogic's proteomics tech (SomaScan, SomaSignal) expands Illumina's multiomics portfolio.
Acquisition funded with cash on hand; financial impact discussed on Feb 5, 2026 earnings call.
Builds on co-development partnership established in 2021 for NGS-based proteomics.

item 2.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ILLUMINA, INC. completed an acquisition involving Standard BioTools Inc. for $350,000,000 in cash (closed 2026-01-30).

Action: acquisition
Counterparty: Standard BioTools Inc.
Consideration: $350,000,000 in cash
Closing: 2026-01-30

Exact text from the filing

BioTools’s mass cytometry and microfluidics businesses (the “Business”). On January 30, 2026, the Company completed the Transaction. The Company paid a purchase price of $350,000,000 in cash, subject to customary adjustments. The Purchase Agreement further provides for, in connection with the revenues generated from certain products and services, (i) royalty

View on SEC.gov

Browse all m&a transactions →

ILLUMINA, INC. filing history →

Source: SEC EDGAR

accession 0001110803-26-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.